BCL2 and cancer: The previously reported senescent cell eliminators ABT263 [11] and ABT737 [23] are BH3 mimetic inhibitors of anti-apoptotic proteins (Bcl-xL, Bcl-2, and Bcl-w) developed for cancer therapy.